INTRODUCTION
The myocardium contains adrenergic receptors (ARs) of two main classes, β and α1. Myocardial β-ARs are studied extensively, and blocking β-ARs in heart failure (HF), when the AR agonist norepinephrine (NE) is elevated, is now a cornerstone of therapy.
Much less is known about myocardial α1-ARs. However, animal and human data suggest that activation of myocardial α1-ARs in HF is adaptive and protective, in contrast with the toxic effects of chronic β-AR stimulation.
α1-ARs exist as three molecular subtypes, α1A, α1B, and α1D. Knockout (KO) mouse models have provided the most convincing evidence for the beneficial effects of α1-AR stimulation, and have begun to reveal the distinct physiological roles of the cardiac α1-subtypes.
1 KO of the two main myocardial α1-AR subtypes, the α1A and α1B, impairs normal post-natal cardiac growth, and causes severe dilated cardiomyopathy and death after pressure overload. 2, 3 In KO models, the role of the α1B subtype appears to be physiological cardiac hypertrophy, 2, 4, 5 whereas the α1A is cardioprotective. 3, 6 Although all three subtypes can constrict peripheral arteries, 4, 7, 8 the cardiac α1D stimulates coronary vasoconstriction. 9, 10 α1-AR gain-of-function in cardiac transgenic models generally supports the KO results, although phenotypes vary greatly with receptor level, promoter, and absence or presence of an activating mutation. Thus, cardiac α1B overexpression can cause hypertrophy, but this can be associated with β-AR down-regulation and late cardiomyopathy. [11] [12] [13] [14] Cardiac α1A overexpression can stimulate contractility and cause cardio-protection, [15] [16] [17] [18] but there can be late fibrosis and sudden death. 19 Recently, we found that modest augmentation of cardiac α1A signaling with a subpressor dose of an α1A-selective agonist can prevent doxorubicin-induced cardiomyopathy in mice. 20 In the human heart, α1-subtype roles have not been studied. However, in human clinical trials, non-selective blockade of all three α1-subtypes caused a two-fold increase in HF in the ALLHAT trial, 21 and a trend toward increased mortality in the VHeFT trial. 22 Non-selective activation of all α1-subtypes in vitro has a robust positive inotropic effect in failing human myocardium. 23, 24 Non-selective α1-activation in vitro also protects against ischemia. [25] [26] [27] These beneficial effects of α1-AR activation suggest a novel interpretation of the harmful results of excessive NE reduction in clinical trials (MOXSE, MOXCON, and BEST), [28] [29] [30] specifically, that some degree of α1-activation is essential in HF. Further consistent with a beneficial or compensatory role for human myocardial α1-ARs, chronic therapy with the cardioprotective β-blocker carvedilol potentiates α1-AR effects, 31 and total α1-ARs are not down-regulated in HF, in contrast with β-ARs that are down-regulated.
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The distinct and important roles of the α1A, α1B, and α1D in mouse heart, and, in human heart, the contrasting harmful effects of non-selective α1-blockade and beneficial effects of non-selective α1-stimulation, emphasize the need to define expression of the α1-subtypes in the human heart. Recently, we found that the α1D is the predominant subtype in human coronary arteries. 35 However, little is known about the α1-subtypes in human myocardium. In fact, prior limited mRNA studies have concluded that the human heart expresses only the α1A, [36] [37] [38] [39] and that mouse models of For qRT-PCR, one μg of RNA was reverse transcribed using SuperScript III Reverse Transcriptase (Invitrogen) with both random hexamers (Invitrogen) and oligodT (Roche). qRT-PCR reactions contained 5% of the cDNA product, primers at 125 nM per reaction, and SYBR Green Master (Roche) with ROX reference dye. All reactions were performed in triplicate in an ABI PRISM 7900HT Sequence Detection System.
Data were analyzed with SDS software version 2.3 (Applied Biosystems).
Relative quantitation of PCR products used the ΔΔCt method. 42 Values for each mRNA are arbitrary units (AU) relative to two reference genes, β-actin and TATAbinding protein (TBP), for improved accuracy, 43 as AU = 2 -CT x 1000, where CT=[(mean target gene C T ) -(mean reference genes C T )].
Radioligand binding
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Data analysis
Results are presented as mean ± SEM. Significant differences (p < 0.05) were tested using one-way ANOVA and Tukey's multiple comparison for more than two groups, or Student's unpaired t-test for two groups, and a normal distribution was assumed for all continuous variables. Linear regression tested for association between mRNA abundance and clinical variables. The F test compared goodness-of-fit to oneor two-site models for competition binding analyses (GraphPad Prism v4.0).
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RESULTS
Patients (Table 1)
We tested α1-AR subtype expression in human myocardium from 21 explanted hearts of 14 transplant recipients and 7 unused donors. As shown in Table 1 , there were 9 non-failing (NF) and 12 failing (F) patients, one-third of which had ischemic cardiomyopathy. NF and F were similar in age and sex, but the mean ejection fraction (EF) was 59 ± 3% in the NF group, and 24 ± 2% in the F group (p<0.0001).
Characterization of NF and F LV myocardium (Figure 1)
To characterize NF and F LV myocardium, we assayed select myocyte and nonmyocyte mRNAs by qRT-PCR, and correlated these with EF. As EF decreased, LV β- MyHC, but only 1% of total in F. Importantly, the levels of the reference genes, β-actin and TBP, were comparable in the NF and F groups ( Figure 1D ).
Competition binding for β-AR subtypes using ICI-118,551, an antagonist selective for the β2-subtype, showed that β1-subtype levels decreased markedly in F, whereas the β2-subtype was not changed ( Figure 1E ). Competition binding with CGP 20712A, a β1-selective antagonist, confirmed these values (data not shown).
In summary, we found in F LV the expected repression of α-MyHC, induction of collagen indicative of fibrosis, and down-regulation of the β1-AR subtype, showing a molecular phenotype similar to prior studies in human HF. 33, [46] [47] [48] ract ze F and F LV myocardiu , we ass ed elect myocyte and m As by q -R nd cor el t d e it .
de e e , LV α1-AR subtype mRNAs in the NF myocardium ( Figure 2 , Table 2 )
To begin to test if all three α1-subtypes were present in human myocardium, we did qRT-PCR with validated primers spanning the long intron in each α1-subtype gene.
We made RNA from transmural samples of myocardium from three regions, LV free wall (LVFW), LV septum (LVS, the LV side of the interventricular septum), and RVFW, all taken at the level of the papillary muscles. Figure 2 (left) shows that the α1A was the predominant α1-subtype mRNA in all NF myocardial regions. The α1B and α1D were present at much lower levels (p < 0.05), and also did not differ among the regions ( Figure 2 ). In NF myocardial LVFW and LVS, the α1A was ~63% of total α1-AR mRNA, the α1B was 22%, and the α1D was 15% (Table 2) .
α1-AR subtype proteins in the NF myocardium (Figures 3-4, Table 2)
We quantified α1-AR subtype protein levels using radioligand binding. Recently, we found that commercial α1-AR antibodies are not specific for α1-ARs, 49 and thus we could not use immunoblot or immunohistochemistry to detect or quantify the α1-subtype proteins.
Saturation radioligand binding in myocardial membranes with amon n n n n ng g g g g g t t t t t th h h h h he e e e e e r r r r r re e e e e eg g g g g gi i i i To detect and quantify the α1-subtype proteins, we used competition for In summary, human NF myocardium expressed all three α1-subtype mRNAs, with a striking predominance of the α1A. However, binding assays detected only the α1A and the α1B, and the α1B was predominant.
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α1-AR subtype mRNAs and binding in the F myocardium (Figures 2-4, Table 2)
The relative pattern of α1-subtype mRNA expression within the F myocardium was identical to NF, with a predominance of α1A mRNA, and no differences between α1B and α1D in any region (Figure 2 right) . Total α1-subtype mRNA levels were also h h h h h h o o o o o on n n n n nl l l l l ly y y y y y a a a a a a l l lo o o o o ow w w w w w------a a a a a af f f f f ff f f f f fi i i i in n n n n ni i i i i it t t t t ty y y y y y bindin n n n n ng g g g g g. . . . . T T T T T Ta a a a a ak k k k k ke e e e e en n n n n n t t t t t similar in F and NF myocardium, although α1A mRNA was increased in F LV (p < 0.05, Table 2 ), and tended to increase in F RV (Figure 2 ).
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Total α1-binding was not reduced in any region of F myocardium ( Figure 3B right). Similarly, binding levels of the α1A and α1B subtypes were not reduced in F myocardium ( Figure 4B ), and the α1D remained undetectable (data not shown). The relative levels of α1A and α1B binding also were unchanged in F LV (Table 2 ), but in RV there was a relative increase in α1A binding in F versus NF (44% versus 27%, p = 0.04) ( Figure 4B ).
In summary, the α1A and α1B were not repressed or down-regulated in the F myocardium. The α1A tended to increase.
Comparison of β-AR subtypes in F myocardium (Table 2, Figure 1)
We measured β-AR subtype mRNAs and binding, to test if the two AR families had distinct regulation in HF. Myocardium from F LV had a significant decrease versus NF in β2-subtype mRNA and β1-subtype binding (Table 2 and Figure 1E ). Stable binding levels in HF of the α1A-and α1B-subtypes and down-regulation of the β1-subtype caused a marked increase in the ratio of binding of α1-ARs to β-ARs, from about ~10% in NF LV to ~20-40% in F LV ( Table 2 ; the 41% α1/β ratio in the F LV in Table 2 is from four samples with α1-and β-binding on the same membranes).
Demographic and clinical variables and myocardial α1-AR mRNA levels ( Figure 5) wn-re e e e e eg g g g g gu u u u u ul l l l l la a a a a at t t t t te e e e e ed d The qRT-PCR results were analyzed to determine whether demographic or clinical factors affected the expression of α1-subtype mRNAs. We found that age, EF, sex, β-blocker use, and CAD had no effect on myocardial total or α1-subtype mRNAs ( Figure 5A-D and data not shown) . On the other hand, β-agonist use was associated with a decrease in both α1B (p = 0.04) and α1D (p < 0.01), but did not affect α1A levels ( Figure 5E ). We compared β-AR mRNAs in a similar analysis, and found that β1-and β2-subtype mRNA levels in myocardium did not change with age, EF, sex, β-blocker use, β-agonist use, or CAD (Online Figure 2 and data not shown). n n n n n n) ) ) ) ) ). .
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DISCUSSION
We present here the first data on α1-AR subtype proteins in human heart, and the first comparison of α1-AR subtypes in NF and F human hearts. The main findings are that the α1A is the predominant α1-subtype mRNA, the α1A and α1B are both present by binding, with the α1B predominant, and the α1D is undetectable by binding.
In HF, α1-subtype mRNAs are not repressed, and α1-binding is not down-regulated, in contrast with β-AR subtypes.
Prior studies of human myocardial α1-AR subtypes used semi-quantitative mRNA assays with a very limited number of undefined patients, and never measured α1-subtype proteins. [36] [37] [38] [39] These studies identified the α1A as the most abundant or only α1-subtype mRNA in myocardium, and a separate study concluded that the α1A was the only α1-subtype in human coronary arteries. 40 These results prompted the conclusion that the human heart is exclusively α1A, and thus that mouse models are irrelevant to human cardiac α1-AR biology. 40, 41 On the contrary, the present and our recent studies show that α1-subtype expression is the same in the human and mouse heart, with the α1A and α1B subtypes in myocardium, and the α1D in coronary arteries.
This is important, because it implies that findings in mouse genetic models, where α1-subtype functions can be studied with precision, are relevant to human cardiac α1-AR biology, in particular, the adaptive and protective effects of the α1A-and α1B-subtypes.
Technical aspects of this study warrant emphasis. Although our patient population was modest in size, it was significantly larger and more thoroughly characterized than in prior studies. We quantified 1-subtype mRNAs in DNase-treated s s s s s se e e e e em m m m m mi i i i i i-u u u u u ua a a a a an n n n n nt t
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α1-subtype in human n n c c co or r r r ro o o o on n na a a a ar r r r ry y y a ar r rt t t t te e e e erie e es s. 40 RNA, using qRT-PCR with carefully evaluated primer pairs that cross the large intron in all 1-AR genes, to eliminate contamination from genomic DNA. We quantified 1-subtype proteins by radioligand binding. Prior studies have used commercial antibodies to measure 1-subtypes in human non-cardiac tissues, but we find that ten different antibodies are not specific for 1-ARs, 49 indicating that binding is currently the only valid method for detecting and quantifying 1-AR proteins. Our membrane preparation for binding was not "purified", i.e. we did not discard any low speed pellets. This meant that we did not discard the large number of receptors that are found in low speed pellets, 1 and also that our denominator of mg protein was higher than in purified membranes.
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A potential technical concern was the discordance between 1-subtype mRNA levels and binding levels. The 1A mRNA in human myocardium was by far most abundant, but 1A binding was less than 1B. The myocardial 1D mRNA was as abundant as 1B, but 1D binding was undetectable. Importantly, the same discordance between the levels of 1A and 1B mRNAs and binding is seen also in the mouse and rat heart, 1, 44 and mouse myocardium has 1D mRNA without 1D binding. Table 2 , to binding of the α1A in NF LV. Normalization provides the following binding ratios in human LV myocardium of α1A:α1B:β1:β2: in NF LV, 1:2:17:7, and in F LV, 1:2:6:7. Thus, the failing human myocardium has potentially much greater relative signaling through the α1A, α1B, and β2 subtypes. The F RV was especially notable, with a significant increase in relative α1A binding (Figure 4) .
Clinical relevance. Loss and gain of function studies in the mouse heart show adaptive and protective effects of stimulation of the α1A and/or α1B subtypes (Introduction), raising the possibility of using α1-subtype-selective agonists as therapy
for HF. We demonstrate here that the α1A and α1B are both present in the human myocardium and are not down-regulated in HF, indicating that this idea might be feasible. Furthermore, the fact that the α1-subtype in human coronary arteries is the α1D suggests that an agonist for the α1A or α1B would not cause coronary constriction. 35 On the other hand, an α1D-selective antagonist might be safe and efficacious in prostate disease, 50 without the potential harmful side effects of nonselective blockade of myocardial α1A and α1B subtypes. 21, 22 Summary. In this study, we characterize the α1-AR subtypes in the non-failing and failing human heart. As in the mouse, the α1A and α1B are the predominant binding subtypes in human myocardium, and the α1D is absent. In contrast to β1-ARs, the α1A and α1B are not down-regulated in HF. Thus, α1-subtypes in the human heart appear to be similar to mouse heart, where adaptive and protective effects of α1-subtypes are 
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